TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 3 Open Label Study to Evaluate the Long-term Safety and Tolerability of ALKS 8700 in Adults With Relapsing Remitting Multiple Sclerosis
Brief Summary: The primary objective of this study is to evaluate the long-term safety and tolerability of ALKS 8700 for the treatment of Relapsing Remitting Multiple Sclerosis (RRMS). The secondary objective of this study is to evaluate treatment effect over time in adult participants with RRMS treated with ALKS 8700.


Options:
A: Arm Label: Part I Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Part I BG00012; Type: EXPERIMENTAL; Interventions: Drug: dimethyl fumarate | Arm Label: Part II BG00012; Type: EXPERIMENTAL; Interventions: Drug: dimethyl fumarate | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Part I Placebo | Intervention Type: DRUG; Name: dimethyl fumarate; Assigned to Arm(s): Part I BG00012, Part II BG00012
B: Arm Label: ALKS 8700; Type: EXPERIMENTAL; Interventions: Drug: ALKS 8700 | Intervention Type: DRUG; Name: ALKS 8700; Assigned to Arm(s): ALKS 8700
C: Arm Label: RNF 44 mcg three times weekly; Type: ACTIVE_COMPARATOR; Interventions: Drug: RNF | Arm Label: RNF 44 mcg once weekly and placebo twice weekly for blinding; Type: ACTIVE_COMPARATOR; Interventions: Drug: RNF, Drug: Placebo | Arm Label: Placebo three times weekly; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: RNF; Assigned to Arm(s): RNF 44 mcg once weekly and placebo twice weekly for blinding, RNF 44 mcg three times weekly | Intervention Type: DRUG; Name: RNF; Assigned to Arm(s): RNF 44 mcg once weekly and placebo twice weekly for blinding, RNF 44 mcg three times weekly | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo three times weekly, RNF 44 mcg once weekly and placebo twice weekly for blinding
D: Arm Label: fingolimod 0.5 mg; Type: EXPERIMENTAL; Interventions: Drug: fingolimod | Arm Label: fingolimod 0.25mg; Type: EXPERIMENTAL; Interventions: Drug: fingolimod | Arm Label: glatiramer acetate 20 mg; Type: ACTIVE_COMPARATOR; Interventions: Drug: glatiramer acetate | Intervention Type: DRUG; Name: fingolimod; Assigned to Arm(s): fingolimod 0.25mg, fingolimod 0.5 mg | Intervention Type: DRUG; Name: glatiramer acetate; Assigned to Arm(s): glatiramer acetate 20 mg

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A 24-Week Multicenter, Randomized, Open-Label, Parallel-Group Study Comparing the Efficacy and Safety of Ixekizumab to Fumaric Acid Esters and Methotrexate in Patients With Moderate-to-Severe Plaque Psoriasis Who Are Naive to Systemic Treatment With an Extension Period
Brief Summary: The main purpose of this study is to evaluate the efficacy of ixekizumab compared to fumaric acid esters (FAE) and methotrexate (MTX) in participants with moderate-to-severe plaque psoriasis who are naive to systemic treatment.


Options:
A: Arm Label: Ixekizumab; Type: EXPERIMENTAL; Interventions: Drug: Ixekizumab | Arm Label: Fumaric Acid Esters; Type: ACTIVE_COMPARATOR; Interventions: Drug: Fumaric Acid Esters, Drug: Ixekizumab | Arm Label: Methotrexate; Type: ACTIVE_COMPARATOR; Interventions: Drug: Methotrexate, Drug: Ixekizumab | Intervention Type: DRUG; Name: Fumaric Acid Esters; Assigned to Arm(s): Fumaric Acid Esters | Intervention Type: DRUG; Name: Methotrexate; Assigned to Arm(s): Methotrexate | Intervention Type: DRUG; Name: Ixekizumab; Assigned to Arm(s): Fumaric Acid Esters, Ixekizumab, Methotrexate
B: Arm Label: Placebo (Part A); Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo for risankizumab | Arm Label: Risankizumab 75 mg (Part A); Type: EXPERIMENTAL; Interventions: Drug: risankizumab, Drug: placebo for risankizumab | Arm Label: Risankizumab 150 mg (Part A); Type: EXPERIMENTAL; Interventions: Drug: risankizumab | Intervention Type: DRUG; Name: risankizumab; Assigned to Arm(s): Risankizumab 150 mg (Part A), Risankizumab 75 mg (Part A) | Intervention Type: DRUG; Name: placebo for risankizumab; Assigned to Arm(s): Placebo (Part A), Risankizumab 75 mg (Part A)
C: Arm Label: Part 1 - Etanercept; Type: ACTIVE_COMPARATOR; Interventions: Drug: Etanercept | Arm Label: Part 2 - Etanercept and nbUVB; Type: ACTIVE_COMPARATOR; Interventions: Drug: Etanercept, Device: nbUVB | Arm Label: Part 2 - Etanercept; Type: ACTIVE_COMPARATOR; Interventions: Drug: Etanercept | Intervention Type: DRUG; Name: Etanercept; Assigned to Arm(s): Part 1 - Etanercept, Part 2 - Etanercept, Part 2 - Etanercept and nbUVB | Intervention Type: DEVICE; Name: nbUVB; Assigned to Arm(s): Part 2 - Etanercept and nbUVB
D: Arm Label: Group I: Guselkumab Plus Placebo; Type: EXPERIMENTAL; Interventions: Drug: Guselkumab, Drug: Placebo | Arm Label: Group II: Secukinumab; Type: ACTIVE_COMPARATOR; Interventions: Drug: Secukinumab | Intervention Type: DRUG; Name: Guselkumab; Assigned to Arm(s): Group I: Guselkumab Plus Placebo | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Group I: Guselkumab Plus Placebo | Intervention Type: DRUG; Name: Secukinumab; Assigned to Arm(s): Group II: Secukinumab

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A 24-Week Multicenter, Randomized, Open-Label, Parallel-Group Study Comparing the Efficacy and Safety of Ixekizumab to Fumaric Acid Esters and Methotrexate in Patients With Moderate-to-Severe Plaque Psoriasis Who Are Naive to Systemic Treatment With an Extension Period
Brief Summary: The main purpose of this study is to evaluate the efficacy of ixekizumab compared to fumaric acid esters (FAE) and methotrexate (MTX) in participants with moderate-to-severe plaque psoriasis who are naive to systemic treatment.


Options:
A: Arm Label: Ixekizumab; Type: EXPERIMENTAL; Interventions: Drug: Ixekizumab | Arm Label: Fumaric Acid Esters; Type: ACTIVE_COMPARATOR; Interventions: Drug: Fumaric Acid Esters, Drug: Ixekizumab | Arm Label: Methotrexate; Type: ACTIVE_COMPARATOR; Interventions: Drug: Methotrexate, Drug: Ixekizumab | Intervention Type: DRUG; Name: Fumaric Acid Esters; Assigned to Arm(s): Fumaric Acid Esters | Intervention Type: DRUG; Name: Methotrexate; Assigned to Arm(s): Methotrexate | Intervention Type: DRUG; Name: Ixekizumab; Assigned to Arm(s): Fumaric Acid Esters, Ixekizumab, Methotrexate
B: Arm Label: Active Treatment 10 mg BID; Type: EXPERIMENTAL; Interventions: Drug: CP-690,550 | Arm Label: Active Treatment 5 mg BID; Type: EXPERIMENTAL; Interventions: Drug: CP-690,550 | Arm Label: Placebo Treatment; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo/CP-690,550 | Intervention Type: DRUG; Name: CP-690,550; Assigned to Arm(s): Active Treatment 10 mg BID | Intervention Type: DRUG; Name: CP-690,550; Assigned to Arm(s): Active Treatment 5 mg BID | Intervention Type: DRUG; Name: Placebo/CP-690,550; Assigned to Arm(s): Placebo Treatment | Intervention Type: DRUG; Name: Placebo/CP-690,550; Assigned to Arm(s): Placebo Treatment
C: Arm Label: Group I (Placebo); Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Group II (Ustekinumab 45 mg); Type: EXPERIMENTAL; Interventions: Drug: Ustekinumab, Drug: Placebo | Arm Label: Group III (Ustekinumab 90 mg); Type: EXPERIMENTAL; Interventions: Drug: Ustekinumab, Drug: Placebo | Arm Label: Group IV; Type: EXPERIMENTAL; Interventions: Drug: Ustekinumab | Arm Label: Group V; Type: EXPERIMENTAL; Interventions: Drug: Ustekinumab | Intervention Type: DRUG; Name: Ustekinumab; Assigned to Arm(s): Group II (Ustekinumab 45 mg), Group III (Ustekinumab 90 mg), Group IV, Group V | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Group I (Placebo), Group II (Ustekinumab 45 mg), Group III (Ustekinumab 90 mg)
D: Arm Label: 30 mg Mirikizumab; Type: EXPERIMENTAL; Interventions: Drug: Mirikizumab | Arm Label: 100 mg Mirikizumab; Type: EXPERIMENTAL; Interventions: Drug: Mirikizumab | Arm Label: 300 mg Mirikizumab; Type: EXPERIMENTAL; Interventions: Drug: Mirikizumab | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Mirikizumab; Assigned to Arm(s): 100 mg Mirikizumab, 30 mg Mirikizumab, 300 mg Mirikizumab | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Clinical Decision Support for Stroke Prevention in Atrial Fibrillation - a Cluster Randomized Trial in the Primary Care Setting
Brief Summary: A cluster randomised study in the primary care setting to evaluate a electronic clinical decision tool for stroke prophylaxis in patients with atrial fibrillation.


Options:
A: Arm Label: Family Decision Support; Type: EXPERIMENTAL; Interventions: Behavioral: Family Decision Support | Arm Label: Clinical Decision Support; Type: EXPERIMENTAL; Interventions: Behavioral: Clinician Decision Support | Arm Label: Family DS+ Clinician DS; Type: EXPERIMENTAL; Interventions: Behavioral: Family Decision Support, Behavioral: Clinician Decision Support, Other: Family Decision Support and Clinician Decision Support | Arm Label: Control; Type: OTHER; Interventions: Other: Control | Intervention Type: BEHAVIORAL; Name: Family Decision Support; Assigned to Arm(s): Family DS+ Clinician DS, Family Decision Support | Intervention Type: BEHAVIORAL; Name: Clinician Decision Support; Assigned to Arm(s): Clinical Decision Support, Family DS+ Clinician DS | Intervention Type: OTHER; Name: Family Decision Support and Clinician Decision Support; Assigned to Arm(s): Family DS+ Clinician DS | Intervention Type: OTHER; Name: Control; Assigned to Arm(s): Control
B: Arm Label: dashboard team care intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Diabetes Dashboard Intervention | Arm Label: usual diabetes team control; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Usual Diabetes Care | Intervention Type: BEHAVIORAL; Name: Diabetes Dashboard Intervention; Assigned to Arm(s): dashboard team care intervention | Intervention Type: BEHAVIORAL; Name: Usual Diabetes Care; Assigned to Arm(s): usual diabetes team control
C: Arm Label: Intervention group; Type: EXPERIMENTAL; Interventions: Other: Clinical Decision Support tool | Arm Label: Control group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Clinical Decision Support tool; Assigned to Arm(s): Intervention group
D: Arm Label: Electronic alert; Type: ACTIVE_COMPARATOR; Interventions: Other: Electronic warning alert | Arm Label: No electronic alert; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Electronic warning alert; Assigned to Arm(s): Electronic alert

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Double-blind, Randomized, Placebo-controlled Phase III Trial to Investigate the Efficacy and Safety of NPC-12G Gel (Topical Formulation of Sirolimus) to Angiofibroma and Other Skin Lesions in Patients With Tuberous Sclerosis Complex
Brief Summary: The purpose of this trial is to evaluate the efficacy and safety of NPC-12G gel (topical formulation of sirolimus) versus placebo gel to facial angiofibroma and other skin lesions in patients with tuberous sclerosis complex (TSC)


Options:
A: Arm Label: Ramaycin; Type: EXPERIMENTAL; Interventions: Drug: Rapamycin | Intervention Type: DRUG; Name: Rapamycin; Assigned to Arm(s): Ramaycin
B: Arm Label: NPC-12G gel; Type: EXPERIMENTAL; Interventions: Drug: NPC-12G gel | Arm Label: Placebo gel; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo gel | Intervention Type: DRUG; Name: NPC-12G gel; Assigned to Arm(s): NPC-12G gel | Intervention Type: DRUG; Name: Placebo gel; Assigned to Arm(s): Placebo gel
C: Arm Label: Everolimus (RAD001); Type: EXPERIMENTAL; Interventions: Drug: Everolimus (RAD001) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Everolimus (RAD001); Assigned to Arm(s): Everolimus (RAD001)
D: Arm Label: TSC Placebo Arm; Type: PLACEBO_COMPARATOR; Interventions: Drug: Skincerity | Arm Label: TSC 1% Arm; Type: EXPERIMENTAL; Interventions: Drug: Skincerity plus sirolimus/rapamycin | Arm Label: TSC 5% Arm; Type: EXPERIMENTAL; Interventions: Drug: Skinercity plus sirolimus/rapamycin | Arm Label: NF1 Placebo Arm; Type: PLACEBO_COMPARATOR; Interventions: Drug: Skincerity | Arm Label: NF1 1% Arm; Type: EXPERIMENTAL; Interventions: Drug: Skincerity plus sirolimus/rapamycin | Arm Label: NF1 5% Arm; Type: EXPERIMENTAL; Interventions: Drug: Skinercity plus sirolimus/rapamycin | Intervention Type: DRUG; Name: Skincerity; Assigned to Arm(s): NF1 Placebo Arm, TSC Placebo Arm | Intervention Type: DRUG; Name: Skincerity plus sirolimus/rapamycin; Assigned to Arm(s): NF1 1% Arm, TSC 1% Arm | Intervention Type: DRUG; Name: Skinercity plus sirolimus/rapamycin; Assigned to Arm(s): NF1 5% Arm, TSC 5% Arm

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Focal Cartilage Defects in the Knee - A Randomized Controlled Trial Comparing Arthroscopic Microfracture With Arthroscopic Debridement
Brief Summary: 114 patients between 18 and 50 years with an isolated focal cartilage defect in the knee will be randomized to either receive arthroscopic microfracture or arthroscopic debridement. Both groups will then undergo a systematic physiotherapy training regime for 6-9 months. The groups will then be compared for results, after 3, 6, 12 and 24 months, by using validated patient reported outcome scores (Lysholm, KOOS, Tegner) and EQ5D as well as clinical examination and radiological findings at 2 years (MRI).


Options:
A: Arm Label: PRP; Type: EXPERIMENTAL; Interventions: Biological: Platelet rich plasma | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BIOLOGICAL; Name: Platelet rich plasma; Assigned to Arm(s): PRP
B: Arm Label: Operative (O); Type: ACTIVE_COMPARATOR; Interventions: Procedure: Operative (partial arthroscopy) | Arm Label: Conservative (K); Type: SHAM_COMPARATOR; Interventions: Procedure: Conservative (diagnostic arthroscopy) | Intervention Type: PROCEDURE; Name: Operative (partial arthroscopy); Assigned to Arm(s): Operative (O) | Intervention Type: PROCEDURE; Name: Conservative (diagnostic arthroscopy); Assigned to Arm(s): Conservative (K)
C: Arm Label: Arthroscopic microfracture (MF); Type: ACTIVE_COMPARATOR; Interventions: Procedure: Arthroscopic microfracture (MF) | Arm Label: Arthroscopic debridement (AD); Type: SHAM_COMPARATOR; Interventions: Procedure: Arthroscopic debridement (AD) | Intervention Type: PROCEDURE; Name: Arthroscopic microfracture (MF); Assigned to Arm(s): Arthroscopic microfracture (MF) | Intervention Type: PROCEDURE; Name: Arthroscopic debridement (AD); Assigned to Arm(s): Arthroscopic debridement (AD)
D: Arm Label: Arthroscopy plus Medical Management; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Arthroscopy plus Medical Management, Other: Medical Management | Arm Label: Medical Management; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: PROCEDURE; Name: Arthroscopy plus Medical Management; Assigned to Arm(s): Arthroscopy plus Medical Management | Intervention Type: OTHER; Name: Medical Management; Assigned to Arm(s): Arthroscopy plus Medical Management

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Continuous Versus Bolus Intermittent Loop Diuretic Infusion in Acutely Decompensated Heart Failure: Evaluation of Renal Function, Congestion Signs, BNP and Outcome
Brief Summary: DiurHF is a prospective, multicenter, observational, study that compares continuous with intermittent infusion of furosemide in patients admitted with a diagnosis of ADHF. Previous pilot study design was planned to anticipate a larger multicenter trial able to definitively evaluate the optimal loop diuretic use strategy in patients with ADHF.


Options:
A: Arm Label: Continuous Furosemide Infusion; Type: N/A; Interventions: Drug: Continuous Furosemide Infusion | Arm Label: Intermittent Furosemide Infusion; Type: N/A; Interventions: Drug: Intermittent Furosemide Infusion | Intervention Type: DRUG; Name: Continuous Furosemide Infusion; Assigned to Arm(s): Continuous Furosemide Infusion | Intervention Type: DRUG; Name: Intermittent Furosemide Infusion; Assigned to Arm(s): Intermittent Furosemide Infusion
B: Arm Label: Ultrafiltration; Type: EXPERIMENTAL; Interventions: Procedure: ultrafiltration | Arm Label: Usual treatment; Type: ACTIVE_COMPARATOR; Interventions: Procedure: ultrafiltration | Intervention Type: PROCEDURE; Name: ultrafiltration; Assigned to Arm(s): Ultrafiltration, Usual treatment
C: Arm Label: Infusional drug treatment; Type: ACTIVE_COMPARATOR; Interventions: Drug: Furosemide or Furosemide and Dopamine | Arm Label: Ultrafiltration; Type: EXPERIMENTAL; Interventions: Device: Ultrafiltration | Intervention Type: DRUG; Name: Furosemide or Furosemide and Dopamine; Assigned to Arm(s): Infusional drug treatment | Intervention Type: DEVICE; Name: Ultrafiltration; Assigned to Arm(s): Ultrafiltration
D: Arm Label: Stepped pharmacologic care; Type: ACTIVE_COMPARATOR; Interventions: Drug: Stepped pharmacologic care | Arm Label: Ultrafiltration; Type: EXPERIMENTAL; Interventions: Device: Ultrafiltration | Intervention Type: DRUG; Name: Stepped pharmacologic care; Assigned to Arm(s): Stepped pharmacologic care | Intervention Type: DEVICE; Name: Ultrafiltration; Assigned to Arm(s): Ultrafiltration

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Prospective, Double-blind, Randomized, Multicenter Phase III Study Evaluating Efficacy and Safety of Three Different Dosages of NewGam in Patients With Chronic Inflammatory Demyelinating Poly(Radiculo)Neuropathy
Brief Summary: Study to evaluate the Efficacy and Safety of Three Different Dosages of NewGam in Patients With Chronic Inflammatory Demyelinating Poly(radiculo)neuropathy


Options:
A: Arm Label: Group 1; Type: EXPERIMENTAL; Interventions: Drug: Immune Globulin IV (Human), 10% Caprylate/Chromatography Purified | Arm Label: Group 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Albumin (Human) 25%, United States Pharmacopeia (USP) | Intervention Type: DRUG; Name: Immune Globulin IV (Human), 10% Caprylate/Chromatography Purified; Assigned to Arm(s): Group 1 | Intervention Type: DRUG; Name: Albumin (Human) 25%, United States Pharmacopeia (USP); Assigned to Arm(s): Group 2
B: Arm Label: 0.5 g/kg NewGam; Type: EXPERIMENTAL; Interventions: Drug: NewGam | Arm Label: 1.0 g/kg NewGam; Type: EXPERIMENTAL; Interventions: Drug: NewGam | Arm Label: 2.0 g/kg NewGam; Type: EXPERIMENTAL; Interventions: Drug: NewGam | Intervention Type: DRUG; Name: NewGam; Assigned to Arm(s): 0.5 g/kg NewGam, 1.0 g/kg NewGam, 2.0 g/kg NewGam
C: Arm Label: NPB-01; Type: EXPERIMENTAL; Interventions: Drug: NPB-01 | Intervention Type: DRUG; Name: NPB-01; Assigned to Arm(s): NPB-01
D: Arm Label: IgPro20 low dose; Type: EXPERIMENTAL; Interventions: Biological: IgPro20 (low dose), Biological: IgPro10 | Arm Label: IgPro20 high dose; Type: EXPERIMENTAL; Interventions: Biological: IgPro10, Biological: IgPro20 (high dose) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo, Biological: IgPro10 | Intervention Type: BIOLOGICAL; Name: IgPro20 (low dose); Assigned to Arm(s): IgPro20 low dose | Intervention Type: BIOLOGICAL; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: BIOLOGICAL; Name: IgPro10; Assigned to Arm(s): IgPro20 high dose, IgPro20 low dose, Placebo | Intervention Type: BIOLOGICAL; Name: IgPro20 (high dose); Assigned to Arm(s): IgPro20 high dose

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 3, Randomized, Double-blind, Placebo-controlled Multicenter Study to Evaluate the Efficacy and Safety of Ospemifene in Patients With Moderate to Severe Vaginal Dryness, a Symptom of Vulvo-vaginal Atrophy (VVA) Due to Menopause
Brief Summary: The objective of this study is to evaluate the efficacy and safety of ospemifene 60 mg once daily (QD) compared with placebo in treatment of vulvo-vaginal atrophy (VVA) due to menopause in women with moderate to severe vaginal dryness as the most bothersome symptom (MBS) of VVA.


Options:
A: Arm Label: faslodex+placebo; Type: EXPERIMENTAL; Interventions: Drug: faslodex 500mg, Drug: arimidex dummy | Arm Label: arimidex +placebo; Type: ACTIVE_COMPARATOR; Interventions: Drug: arimidex 1mg, Drug: faslodex dummy | Intervention Type: DRUG; Name: faslodex 500mg; Assigned to Arm(s): faslodex+placebo | Intervention Type: DRUG; Name: arimidex 1mg; Assigned to Arm(s): arimidex +placebo | Intervention Type: DRUG; Name: faslodex dummy; Assigned to Arm(s): arimidex +placebo | Intervention Type: DRUG; Name: arimidex dummy; Assigned to Arm(s): faslodex+placebo
B: Arm Label: Ospemifene; Type: EXPERIMENTAL; Interventions: Drug: Ospemifene | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Ospemifene; Assigned to Arm(s): Ospemifene | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: CO2 fractionated vaginal laser; Type: EXPERIMENTAL; Interventions: Device: CO2 fractionated vaginal laser | Arm Label: Estrogens, Conjugated (USP); Type: ACTIVE_COMPARATOR; Interventions: Drug: Estrogens, Conjugated (USP) | Intervention Type: DEVICE; Name: CO2 fractionated vaginal laser; Assigned to Arm(s): CO2 fractionated vaginal laser | Intervention Type: DRUG; Name: Estrogens, Conjugated (USP); Assigned to Arm(s): Estrogens, Conjugated (USP)
D: Intervention Type: DRUG; Name: estradiol, 25 mcg; Assigned to Arm(s): N/A

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effects of Blastocyst Stage Embryo Transfer Compared With Cleavage Stage Embryo Transfer in Women ≤ 38 Years
Brief Summary: Single center randomized study including 388 women aged less than 39 years, performing in vitro fertilization, to determine if blastocyst stage (Day 5 to 6) embryo transfer (ETs) improves implantation and pregnancy rate compared with cleavage stage (Day 2 to 3) ETs.


Options:
A: Arm Label: Frozen Embryo Transfer with PGD; Type: EXPERIMENTAL; Interventions: Other: PGD | Arm Label: Fresh Embryo Transfer with PGD; Type: EXPERIMENTAL; Interventions: Other: PGD | Intervention Type: OTHER; Name: PGD; Assigned to Arm(s): Fresh Embryo Transfer with PGD, Frozen Embryo Transfer with PGD
B: Arm Label: Blastocyst; Type: EXPERIMENTAL; Interventions: Procedure: Embryo transfer | Arm Label: Cleavage; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Embryo transfer | Intervention Type: PROCEDURE; Name: Embryo transfer; Assigned to Arm(s): Blastocyst, Cleavage
C: Arm Label: Blastocyst transfer in PTEC cycle; Type: EXPERIMENTAL; Interventions: Procedure: Embryo cryopreservation | Arm Label: Fresh blastocyst transfer.; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Fresh blastocyst transfer | Intervention Type: PROCEDURE; Name: Embryo cryopreservation; Assigned to Arm(s): Blastocyst transfer in PTEC cycle | Intervention Type: PROCEDURE; Name: Fresh blastocyst transfer; Assigned to Arm(s): Fresh blastocyst transfer.
D: Arm Label: Freeze-all protocol; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Freeze-all protocol | Arm Label: Fresh transfer protocol; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Fresh transfer protocol | Intervention Type: PROCEDURE; Name: Freeze-all protocol; Assigned to Arm(s): Freeze-all protocol | Intervention Type: PROCEDURE; Name: Fresh transfer protocol; Assigned to Arm(s): Fresh transfer protocol

Answer: B